Genmab 과거 수익 실적

과거 기준 확인 4/6

Genmab은 연평균 10.2%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 수입이 증가했으며, 연간 7.7%였습니다. 매출은 연평균 23.8%의 비율로 증가했습니다. Genmab의 자기자본이익률은 14.7%이고 순이익률은 23.7%입니다.

주요 정보

10.2%

수익 성장률

10.0%

EPS 성장률

Biotechs 산업 성장	-14.6%
매출 성장률	23.8%
자기자본 수익률	14.7%
순이익	23.7%
최근 수익 업데이트	30 Sep 2024

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

Genmab 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

BST:GE91 수익, 비용 및 수입 (DKK Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Sep 24	19,844	4,702	3,475	9,032
30 Jun 24	19,016	5,540	3,470	8,773
31 Mar 24	17,783	5,467	3,478	8,189
31 Dec 23	16,474	4,352	3,297	7,630
30 Sep 23	16,852	4,163	3,284	7,285
30 Jun 23	16,227	4,641	3,094	6,683
31 Mar 23	15,220	5,197	2,900	6,112
31 Dec 22	14,505	5,452	2,676	5,524
30 Sep 22	11,987	5,654	2,267	5,219
30 Jun 22	10,210	3,962	1,903	4,847
31 Mar 22	9,020	2,377	1,534	4,486
31 Dec 21	8,417	2,957	1,283	4,181
30 Sep 21	7,907	2,873	1,002	3,787
30 Jun 21	7,321	2,513	841	3,394
31 Mar 21	10,800	5,585	756	3,248
31 Dec 20	10,111	4,758	661	3,137
30 Sep 20	11,028	5,649	546	2,880
30 Jun 20	10,344	5,656	483	2,766
31 Mar 20	5,667	2,363	377	2,555
31 Dec 19	5,366	2,166	342	2,386
30 Sep 19	3,641	1,528	285	2,173
30 Jun 19	3,199	1,170	258	1,910
31 Mar 19	2,935	1,345	241	1,664
31 Dec 18	3,025	1,472	214	1,431
30 Sep 18	2,807	1,424	195	1,227
30 Jun 18	2,532	1,239	177	1,112
31 Mar 18	2,796	1,286	157	995
31 Dec 17	2,365	1,104	147	852
30 Sep 17	2,275	1,159	131	795
30 Jun 17	2,316	1,354	121	718
31 Mar 17	1,897	1,215	110	704
31 Dec 16	1,816	1,187	102	661
30 Sep 16	1,463	735	101	642
30 Jun 16	1,376	686	94	606
31 Mar 16	1,196	535	93	529
31 Dec 15	1,133	764	91	488
30 Sep 15	774	443	92	443
30 Jun 15	768	463	90	441
31 Mar 15	710	420	86	459
31 Dec 14	850	301	80	506
30 Sep 14	851	292	77	517
30 Jun 14	729	138	72	534
31 Mar 14	751	138	69	545
31 Dec 13	664	70	67	528

양질의 수익: GE91 은 높은 수익을 보유하고 있습니다.

이익 마진 증가: GE91 의 현재 순이익 이익률 (23.7%) 작년보다 낮습니다 (24.7%).

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: GE91 의 수입은 지난 5년 동안 매년 10.2% 씩 증가했습니다.

성장 가속화: 지난 1년간 GE91 의 수익 증가율( 12.9% )은 연간 평균( 10.2% 초과합니다. ).

수익 대 산업: 지난 1년간 GE91 수익 증가율( 12.9% )은 Biotechs 업계 -18.2% 초과했습니다.

자기자본 수익률

높은 ROE: GE91 의 자본 수익률( 14.7% )은 낮음으로 간주됩니다.

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/18 11:48
장 마감 주가	2024/11/15 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Genmab A/S 45 애널리스트 중 23 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Andrew Carlsen	ABG Sundal Collier
Armelle Moulin	AlphaValue
Emily Field	Barclays

Genmab 과거 수익 실적

과거 기준 확인 4/6

주요 정보

최근 과거 실적 업데이트

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Recent updates

Genmab A/S Announces New Results from the Phase 1b/2 EPCORE NHL-2 Trial

Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Genmab A/S Takes Full Control of Acasunlimab Development Program

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Revises Earnings Guidance for the Year 2023

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Genmab A/S Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (Bla) for Epcoritamab (Duobody®-Cd3xcd20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (Lbcl)

Genmab Provides Earnings Guidance for Year 2022

Genmab A/S Submits Biologics License Application to the U.S. Food and Drug Administration

Genmab A/S Revises Earnings Guidance for the Year 2022

Genmab A/S Submits Biologics License Application to U.S. Food and Drug Administration for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

Genmab A/S Revises Earnings Guidance for 2022

AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Genmab A/S Elects Elizabeth O’Farrell to the Board of Directors

Genmab A/S Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer

Genmab A/S Provides Earnings Guidance for the Year 2022

Genmab A/S Provides Earnings Guidance for the Year 2022

Genmab A/S Announces Janssen Received Conditional European Marketing Authorization for RYBREVANT

U.S. Food and Drug Administration Grants Approval to TIVDAK

Seagen Inc. and Genmab A/S Announce FDA Accelerated Approval for TIVDAK™ (Tisotumab Vedotin-Tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer

Genmab A/S Announces the Lancet Published the Results of FIH Trial

Genmab A/S Improves Revenue Guidance for the Full Year of Fiscal 2021

Genmab A/S Announces That Janssen Has Received European Marketing Authorizations for Darzalex® (Daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-Chain (Al) Amyloidosis

Genmab Announces Janssen Received Positive CHMP Opinion Recommending DARZALEX (daratumumab) Subcutaneous (SC) Formulation for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis

Genmab Announces Abstracts Evaluating Products in Pipeline, Portfolio to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress

Genmab A/S Reaffirms Financial Guidance for Fiscal 2021

Genmab A/S Provides Revenue Guidance for the Full Year of Fiscal 2021

Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines

Seagen Inc. and Genmab A/S Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer